Loading
CanSino Biologics Inc. Stock: price and insider trades · Hong Kong
No insider purchase over the last 90 days. The latest, by Chao Shou Bai, was filed 30 Mar 2026.
CanSino Biologics Inc.: what insiders have been doing
Every trade that managers of CanSino Biologics Inc. disclose to HKEX is tracked on this page. The company sits in the Health Care sector and is based in Tianjin, People's Republic of China. It was founded in 2009. Between 25 October 2025 and 25 October 2026, 3 insiders published 3 filings.
The flow runs one way only: 3 insiders bought (3 purchases) and nobody sold on the market. The totals do not cover 3 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket.
With 3 filings in twelve months, the company is quieter than the median of 5 filings across the 750 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 3 purchases and no sales.
The clock since the last published purchase (30 March 2026) now reads 209 days.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
3
Thresholds
n/a
Buy Volume
n/a
3 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleChao Shou Bai1 buy
Wang Jing1 buy
Yu Xuefeng1 buy
Since the insiders bought
- -26.3%Entry HK$31.20 · Close at T+90 HK$22.98
- -26.3%Entry HK$31.20 · Close at T+90 HK$22.98
- -26.3%Entry HK$31.20 · Close at T+90 HK$22.98
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 19,863 of 26,316 companies
34.0
score / 100
Value24
Quality44
FCF yld-2.9%
Earn yld0.5%
EV/EBITDA29.7x
ROE-0.0%
Gross mgn75%
Net mgn2.6%
Debt/EBITDA5.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
HK$23.38
Analyst consensus
4 analysts1.25/5
HK$46.46Target HK$50.45(+116%)HK$53.67
Income statement
RevenueHK$1.1B
Gross profitHK$799.3M75% margin
EBITDAHK$238M22% margin
Net incomeHK$27.9M-0.1% margin
Valuation
PER (trailing)179.8x
PER (forward)18.0x
P/Book1.0x
Beta1.20
Balance sheet & cash
Market capHK$5.8B
Total debtHK$1.3B
Free Cash Flow-HK$166M
Debt / Equity24%
Profitability & ownership
ROE-0.0%
ROA-0.8%
% insiders26.9%
% institutions16.2%
Last declaration on 30 March 2026
Declarations3 total
162,500 sharesShareXHKGHKEX:DA20260330E00022
Canonical exit: 25 Dec 2025 (T+90)
103,700 sharesShareXHKGHKEX:DA20260330E00001
Canonical exit: 25 Jan 2026 (T+90)
371,300 sharesShareXHKGHKEX:DA20260330E00025
Canonical exit: 25 Dec 2025 (T+90)
3 of 3 declarations
About CanSino Biologics Inc.
CanSino Biologics Inc. is a biopharmaceutical company focused on the development of innovative vaccines and therapies. It is listed on the Hong Kong Stock Exchange under the symbol XHKG.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
